Santaris Can't Skirt Isis Suit Over Drug Development Deals

Law360, New York (September 20, 2012, 5:46 PM EDT) -- A California federal judge on Wednesday refused to let Santaris Pharma A/S Corp. off the hook in Isis Pharmaceuticals Inc.'s infringement suit accusing its competitor of leveraging Isis' patented gapmer antisense drug development platform to sign multimillion-dollar deals with industry giants.

U.S. District Judge Barry T. Moskowitz denied Sanrtis’ summary judgment motion without prejudice, saying the company has not convinced him its conduct falls under a federal safe harbor statute.

“The court finds that the facts introduced by Santaris by way of the declaration of one...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.